Taysha Gene Therapies grants new hires 384,000 RSUs, options for 92,400 shares under inducement plan

By Public Technologies
  • Taysha Gene Therapies granted four new employees 384,000 restricted stock units under its 2023 Inducement Plan.
  • Each RSU award vests in four equal annual installments starting on the first anniversary of the vesting commencement date.
  • The company also issued options covering 92,400 shares with an exercise price of $4.74.
  • Options run for 10 years. Vesting spans four years, with 25% after one year, then monthly over 36 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020800PRIMZONEFULLFEED9838327) on October 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.